Logo Image
|Articles|March 1, 2019

Achieve More with PDA

PDA is the leading global provider of science, technology, regulatory information, and education for the bio/pharmaceutical community.

PDA is the leading global provider of science, technology, regulatory information, and education for the bio/pharmaceutical community. For more than 70 years, PDA has been committed to developing sound, practical technical information and resources to advance science and regulation through the expertise of our more than 10,500 members worldwide. We promote dialogue on new technologies and regulations to ensure high-quality pharmaceutical production.

Parenteral Drug Association
INTERPHEX Booth #1653

Related to this article

View more
The BioPharm Brief: A $7 Billion Oncology Option Deal, a TL1A Pivot, and Oral Adalimumab Heads to the Clinic
The BioPharm Brief: A $7 Billion Oncology Option Deal, a TL1A Pivot, and Oral Adalimumab Heads to the Clinic
Boehringer Ingelheim licenses six preclinical ADC and T-cell engager programs from Sino Biopharmaceutical in a deal worth up to $7 billion, Spyre Therapeutics drops anti-TL1A antibody SPY072 in rheumatic diseases after phase 2 misses and turns to hidradenitis suppurativa, and Biora Therapeutics gets ethics approval for a first-in-human trial of its BioJet oral adalimumab capsule.
Read more
The Promise of Microgravity for R&D and Manufacturing
The Promise of Microgravity for R&D and Manufacturing
As access to low Earth orbit expands, space-based research is opening possibilities in drug discovery, formulation, and manufacturing. In Part 1, the authors look at how microgravity changes biology and chemistry in ways that can’t be reproduced on Earth and where it fits from target discovery to life cycle management.
Read more